BIAF
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.51
−5.90%Oct 9, 2026, 20:34 UTC
bioAffinity Technologies appointed WallachBeth Capital LLC as exclusive placement agent on a best-efforts basis for the offering.
Oct 9, 2026, 20:34 UTC
bioAffinity Technologies entered into a securities purchase agreement to sell 116,545 common shares and pre-funded warrants for 536,836 shares, and issued warrants for 980,072 shares in a private placement expected to generate approximately $4 million in gross proceeds.
Oct 8, 2026, 12:00 UTC
bioAffinity Technologies, Inc. announced that it received notice of allowance for a Japanese patent covering its noninvasive CyPath Lung diagnostic test and AI-built algorithm.
Source:Oct 6, 2026, 13:19 UTC
bioAffinity Technologies reported that sales of its CyPath Lung test increased more than 100% through the third quarter of 2026 compared with 2025.
Source:Sep 30, 2026, 12:00 UTC
bioAffinity Technologies entered a distribution partnership with veteran-owned AvMEDICAL to promote its noninvasive CyPath Lung cancer test, and the two companies jointly presented the test for the first time under the agreement at the NAVREF 2026 Annual Conference.
Source:Sep 22, 2026, 12:00 UTC
bioAffinity Technologies announced it will present positive clinical and veteran-focused data on its CyPath Lung diagnostic test at the NAVREF 2026 Annual Conference.
Source:Sep 17, 2026, 12:00 UTC
bioAffinity Technologies announced that it was granted a Hong Kong patent covering the proprietary technology behind its noninvasive CyPath Lung lung cancer diagnostic.
Source:Aug 18, 2026, 12:00 UTC
bioAffinity Technologies and AvMEDICAL announced a nationwide federal healthcare distribution agreement for CyPath Lung, expanding sales reach and access to government healthcare systems.
Source:Aug 14, 2026, 00:00 UTC
bioAffinity Technologies, Inc. completed a private placement on August 12, 2026, issuing pre-funded warrants, Series A warrants, and Series B warrants, raising approximately $4 million in gross proceeds.
Aug 7, 2026, 12:00 UTC
bioAffinity Technologies reported its financial results for the second quarter of 2026.
Source:Jul 22, 2026, 12:08 UTC
bioAffinity Technologies and Pictor, Inc. partner to develop and commercialize bioAffinity's diagnostics for asthma and COPD.
Source:Jul 7, 2026, 12:46 UTC
bioAffinity Technologies reported that quarterly sales of its CyPath Lung diagnostic doubled to a new record, with more than 200% year-over-year growth.
Source:Jun 17, 2026, 13:25 UTC
bioAffinity Technologies priced a public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at $0.80 per share for aggregate gross proceeds of $3.2 million.